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Experimental autoimmune encephalomyelitis (EAE), a Th1-mediated inflammatory disease 
of the central nervous system (CNS), is a model of human multiple sclerosis. Cytosolic 
phospholipase A
 
2
 
 
 
 (cPLA
 
2
 
 
 
), which initiates production of prostaglandins, leukotrienes, 
and platelet-activating factor, is present in EAE lesions. Using myelin oligodendrocyte 
glycoprotein (MOG) immunization, as well as an adoptive transfer model, we showed that 
cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice are resistant to EAE. Histologic examination of the CNS from MOG-
immunized mice revealed extensive inflammatory lesions in the cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice, whereas 
the lesions in cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice were reduced greatly or completely absent. MOG-specific 
T cells generated from WT mice induced less severe EAE in cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice compared with 
cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice, which indicates that cPLA
 
2
 
 
 
 plays a role in the effector phase of EAE. 
Additionally, MOG-specific T cells from cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice, transferred into WT mice, induced 
EAE with delayed onset and lower severity compared with EAE that was induced by control 
cells; this indicates that cPLA
 
2
 
 
 
 also plays a role in the induction phase of EAE. MOG-
specific T cells from cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice were deficient in production of Th1-type cytokines. 
Consistent with this deficiency, in vivo administration of IL-12 rendered cPLA
 
2
 
 
 
 
 
/
 
 
 
 
mice susceptible to EAE. Our data indicate that cPLA
 
2
 
 
 
 plays an important role in EAE 
development and facilitates differentiation of T cells toward the Th1 phenotype.
 
Experimental autoimmune encephalomyelitis
(EAE) is a T cell–mediated inflammatory disease
of the central nervous system (CNS), which
clinically manifests as ascending paralysis. It can
be induced in susceptible animals by immunizing
them with myelin proteins or by injecting them
with myelin protein–specific CD4
 
 
 
 T cells.
EAE shares many clinical and pathologic features
with multiple sclerosis (MS), and is a commonly
used animal model of this human autoimmune
disease (1–3).
MS and EAE are believed to be Th1-
induced autoimmune diseases because of the
increased expression of Th1 cytokines in the
affected CNS and because injection of myelin-
specific Th1, but not Th2, cells into immuno-
competent mice is sufficient to induce EAE
(4–9). Members of the Th1-inducing family of
cytokines, IL-12, -23, and -27, seem to be
important for Th1 differentiation and EAE
development (10–12). IL-12, composed of p35
and p40 subunits, is a prototypic Th1 cytokine
that induces differentiation of Th1 cells (13, 14).
Its role in EAE was proposed based on studies
that showed that adding IL-12 to the cultures of
the encephalitogenic cells greatly exacerbated
EAE, whereas administration of anti-p40 anti-
bodies ameliorated EAE (10, 15). However,
later studies suggested that IL-23, which has the
same p40 subunit as IL-12, may be more critical
than IL-12 in the development of EAE (11, 16).
Recent studies using anti-p28 antibodies, which
block IL-27, suggested that IL-27 also may be
necessary for EAE development (12).
In addition to Th1-type cytokines, many
other mediators of inflammation are increased
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during EAE and MS development; it is likely that a subset of
these may be therapeutically useful targets in MS. Lipid me-
diators of inflammation, including prostaglandins (PGs), leu-
kotrienes (LTs), and platelet-activating factor (PAF), are ele-
vated in the cerebrospinal fluid (CSF) of patients who have
MS (17–19). Cytosolic phospholipase A
 
2
 
 
 
 (cPLA
 
2
 
 
 
) initiates
the production of these inflammatory mediators (20, 21); is
expressed by endothelial cells, CD4
 
 
 
 T cells, and macro-
phages at the site of EAE lesions (22); and is activated by
monocyte chemoattractant protein (MCP)-1 and -3, mono-
cyte inflammatory protein–1
 
 
 
, and regulated on activation,
normal T cell expressed and secreted (23, 24), which are
chemokines that are believed to play a role in EAE and MS
(25). These chemokines stimulate the phosphorylation and
translocation of cPLA
 
2
 
 
 
, and lead to selective release of
arachidonic acid (AA) from phospholipid membranes. The
free AA is converted to PG by way of the cyclooxygenase
pathway, and LTB
 
4
 
 and cysteinyl leukotrienes by way of the
5-lipoxygenase (5-LO) pathway. Concurrent with the re-
lease of AA, lysophosphatidylcholine is generated, which
serves as the precursor for the proinflammatory PAF (26,
27). In addition to being converted into proinflammatory
mediators, AA can be converted into lipoxins that may pro-
mote resolution of inflammation (28, 29) or peroxisome
proliferator-activated receptor 
 
 
 
 agonists, including 15-
hydroxyeicosatetraenoic acid (30). Agonists of peroxisome
proliferator-activated receptor 
 
 
 
 were shown to regulate
macrophage and T cell functions negatively and to reduce
the severity of EAE (31).
The roles of different end-products of cPLA
 
2
 
 
 
 enzy-
matic activity in EAE development are not well understood,
but Kalyvas and David (22), who documented the presence
of cPLA
 
2
 
 
 
 at the site of lesions, also demonstrated that
arachidonyl trifluoromethylketone (AACOCF3)—which
inactivates cPLA
 
2
 
 
 
 by reversible reaction with the active site
serine (32)—can reduce EAE severity in myelin oligoden-
drocyte glycoprotein (MOG)-immunized mice. AACOCF3
was effective at blocking the onset of disease, and, in some
cases, preventing relapse. However, AACOCF3 also inhibits
calcium-independent phospholipase A
 
2
 
 (33), and thrombox-
ane synthase, which is downstream of cyclooxygenase (32).
AACOCF3 also inhibits fatty acid amide hydrolase, the en-
zyme that degrades the natural ligands for the cannabinoid
receptors (34, 35), and cannabinoid receptor agonists ame-
liorate clinical EAE and suppress inflammatory cytokines
in a Theiler virus–induced model of EAE (36). Thus,
AACOCF3 may be acting on multiple enzymes, and there-
fore, its effect in EAE may not be due solely to inhibition
of cPLA
 
2
 
 
 
.
To assess the role of cPLA
 
2
 
 
 
 in EAE, we established
the cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice on the susceptible B6 background,
and studied the development of disease in cPLA
 
2
 
 
 
 
 
/
 
 
 
 and
cPLA
 
2
 
 
 
 
 
/
 
 
 
 littermates. We found that cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice are
resistant to EAE induction. We demonstrated that this resis-
tance is accompanied by a defect in development of Th1 re-
sponses and can be restored by administration of IL-12.
 
RESULTS
cPLA
 
2
 
 
 
   
 
 mice do not develop EAE after immunization 
with MOG
 
To test if end-products of cPLA
 
2
 
 
 
 enzymatic activity were
increased during EAE development, we measured products
of the cyclooxygenase and 5-LO pathways in spinal cords of
naive mice, as well as mice at the onset, peak, and recovery
of the disease. Very low levels of these mediators were found
in the spinal cords of naive mice. Conversely, levels of PGE
 
2
 
and LTB
 
4
 
 were increased significantly (P 
 
 
 
 0.05) at the peak
and during the recovery phase of EAE (Fig. 1).
To test the potential role of cPLA
 
2
 
 
 
 in EAE develop-
ment, we immunized cPLA
 
2
 
 
 
 
 
/
 
 
 
 or cPLA
 
2
 
 
 
 
 
/
 
 
 
 littermates
with MOG and followed EAE development. In three inde-
pendent experiments, cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice were resistant to EAE
induction (3 out of 27 mice developed EAE), whereas
cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice developed severe EAE (22 out of 23 mice
developed EAE) (Fig. 2). There was no difference in the se-
verity of EAE between cPLA
 
2
 
 
 
 
 
/
 
 
 
 and cPLA
 
2
 
 
 
 
 
/
 
 
 
 litter-
mates (unpublished data); therefore, the cPLA
 
2
 
 
 
 
 
/
 
 
 
 litter-
mates were used as controls for cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice in all further
experiments. Microscopic examination of the brain and spinal
cord showed remarkable differences between the cPLA
 
2
 
 
 
 
 
/
 
 
 
and cPLA
 
2
 
 
 
 
 
/
 
 
 
 mice (Fig. 3; Table I). The cPLA2  /  mice
had numerous multifocal to coalescing inflammatory cell in-
filtrates in the brain and spinal cord (Fig. 3), and all cPLA2  / 
mice had infiltrates in the brain and spinal cord. Infiltrates
were present in the leptomeninges, around blood vessels in
the leptomeninges and white matter, and in the parenchyma
Figure 1. Lipid mediators are increased in spinal cords of mice 
with EAE. Mice were killed and perfused extensively with PBS. Spinal 
cords from naive mice (N), or mice with onset (O), peak (P), or recovery 
(R) of EAE were isolated, extracted with methanol, and levels of PGE2 (A) 
and LTB4 (B) were measured using ELISA. Levels of PGE2 and LTB4 were 
increased significantly at peak and recovery of EAE (P   0.05).JEM VOL. 202, September 19, 2005 843
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of the white matter; in the brain they also were localized
around the ventricles. Infiltrates in most animals consisted of
mononuclear cells, primarily lymphocytes, macrophages, and
glial cells. Occasionally, neutrophils and fewer eosinophils
also were observed, although in one cPLA2  /  mouse they
approached 50% of the infiltrating cells. Pallor and vacuola-
tion were associated with the inflammatory cell infiltrates,
which were consistent with edema and demyelination, and
dilated axons were observed sometimes. Changes were more
common in the posterior sections of spinal cord, compared
with the anterior sections. Luxol fast blue stains showed de-
myelination at the sites of inflammatory cell infiltrates. In
contrast, brains from two out of six cPLA2  /  mice and spi-
nal cords from three out of six cPLA2  /  mice had no infil-
trates in any section examined. When present, the changes
in cPLA2  /  mice were much less severe compared with
cPLA2  /  mice (Fig. 3). In addition, infiltrates tended to be
less common in the parenchyma of the brain and spinal cord
of cPLA2  /  mice compared with cPLA2  /  mice. Similar
to cPLA2  /  mice, the infiltrates in cPLA2  /  mice were
primarily mononuclear cells.
To determine if cPLA2  /  mice had defective priming
of MOG-specific T cells in vivo, we tested antigen-specific
proliferation of LN T cells against the immunizing antigen.
Figure 2. cPLA2  /  mice are resistant to EAE induction by immu-
nization with MOG. cPLA2  /  or cPLA2  /  mice were immunized with 
MOG/CFA and injected with pertussis toxin on day 0. Paralysis (clinical 
evidence of EAE) was assessed, starting on day 5 after immunization. Animals 
were scored as follows: 1, limp tail; 2, partial hind leg paralysis; 3, complete 
hind leg paralysis or partial hind and front leg paralysis; 4, complete hind 
and partial front leg paralysis; 5, complete hind and partial or complete 
front paralysis with severely reduced responsiveness to external stimuli. 
Data are shown as a mean clinical score   SE of eight cPLA2  /  and seven 
cPLA2  /  mice. The incidence of EAE was 100% for cPLA2  /  and 0% for 
cPLA2  /  mice. Data are representative of three independent experiments.
Figure 3. Microscopic changes in transverse sections of spinal cords 
from cPLA2  /  and cPLA2  /  mice immunized with MOG/CFA and 
injected with pertussis toxin. Low magnification of thoracolumbar spinal 
cord from cPLA2  /  (A) and cPLA2  /  (B) mice. Bars, 0.2 mm. (A) Multifocal 
to coalescing inflammation in the leptomeninges, around blood vessels in the 
leptomeninges and white matter, and parenchyma of the white matter 
(several areas of inflammation shown by arrows), representative of changes in 
cPLA2  /  mice. There also is vacuolation in the white matter that is con-
sistent with edema. (B) No inflammation in cPLA2  /  mouse. Inflammation 
was absent in 50% of cPLA2  /  mice. (C and D). Higher magnification of 
spinal cords, dorsolateral lumbar region from cPLA2  /  (C) and cPLA2  /  
(D) mice. Bars, 0.05 mm. The spinal nerve is in the upper left. (C). Intense 
inflammation in the leptomeninges and white matter of the spinal cord, 
representative of changes in cPLA2  /  mice. A few dilated axons also
are present. (D) When present, inflammation was much less severe in 
cPLA2  /  mice, and was primarily in the leptomeninges.
Table I. Microscopic changes in CNS of cPLA2     and cPLA2     mice immunized with MOG
Spinal cord
Brain Cervical Thoracic Lumbar
Group Incidencea Mean no. of focib Incidence Mean no. of foci Incidence Mean no. of foci Incidence Mean no. of foci
(%) (%) (%) (%)
cPLA2     6/6c (100) 36.0   4.9 6/6 (100) 26.0   5.7 6/6 (100) 33.0   4.3 6/6 (100) 47.2   23.8
cPLA2     4/6 (67) 4.8   2.2d 1/6 (17) 4.3e   4.3 3/6 (50) 4.0d   3.2 3/6 (50) 6.3e   2.9
aMice with any inflammatory cell infiltrates were considered positive.
bMean number of foci of  20 inflammatory cells   SEM.
cNumber of mice affected/number of mice examined (%).
dP   0.0005 compared with cPLA2    .
eP   0.005 compared with cPLA2  / .cPLA2 -DEFICIENT MICE ARE RESISTANT TO EAE | Marusic et al. 844
When stimulated with a wide range of concentrations of
MOG in vitro, cells that were isolated from the draining LNs
of the immunized cPLA2  /  and cPLA2  /  mice prolifer-
ated similarly (Fig. 4). The same results were obtained when
purified T cells were isolated from the draining LNs and
stimulated with MOG in the presence of WT irradiated B6
spleen cells used as APCs (unpublished data).
cPLA2  plays important roles in the induction 
and the effector phases of EAE
After establishing that cPLA2  /  mice are resistant to EAE de-
velopment when immunized with MOG, we sought to deter-
mine if cPLA2  plays a role in the induction or effector phases
of EAE, or both. To examine these possibilities, we developed a
robust EAE adoptive transfer model in B6 mice.
We tested multiple procedures of inducing EAE in B6
mice using an adoptive transfer model, and were able to
identify conditions under which robust EAE develops in
nearly 100% of the recipient mice (Table S1, available at
http://www.jem.org/cgi/content/full/jem.20050665). We
were able to generate encephalitogenic cells from spleen and
draining LNs of immunized donor animals. To induce EAE,
spleen or LN cells from the immunized donors needed to be
cultured with exogenous IL-12, and the recipient mice
needed to be irradiated sublethally (500 R). EAE was in-
duced with as few as 5.8   106 cultured spleen cells. We also
isolated CD4  cells at the end of the culture period; 3 mil-
lion of these purified CD4  T cells were able to transfer
EAE (unpublished data). In all further adoptive transfer ex-
periments, spleens from the immunized mice were used as a
source of encephalitogenic T cells and the recipient mice
were irradiated sublethally.
To address whether cPLA2  plays a role in the effector
phase of EAE, we tested the ability of encephalitogenic cells
that were generated from immunized WT animals to induce
EAE in cPLA2  /  or cPLA2  /  mice. In three indepen-
dent experiments, cells that were isolated from WT mice in-
duced less severe EAE in cPLA2  /  mice than in cPLA2  / 
control mice (Fig. 5 A). The day of onset of EAE was the
same in both groups of recipient mice. These results indicate
that cPLA2  plays a role in the effector phase of EAE. How-
ever, because a complete absence of clinical EAE never was
observed in cPLA2  /  mice that received encephalitogenic
cells from WT animals, we tested the possibility that cPLA2 
also plays a role in the induction of the encephalitogenic im-
mune responses. We immunized cPLA2  /  or cPLA2  / 
mice with MOG, and used the cells that were derived from
Figure 4. Proliferation of antigen-specific T cells is not impaired in 
cPLA2  /  mice. cPLA2  /  or cPLA2  /  mice were immunized at the 
base of the tail with MOG/CFA, and inguinal LNs were collected 10 d later. 
T cell proliferation was measured in the presence of various concentrations 
of MOG. Cells were cultured for 48 h and pulsed with [3H]thymidine during 
the additional 14–18 h of culture. Data are shown as mean   SD of six 
wells and are representative of two independent experiments.
Figure 5. cPLA2  plays a role in the effector and in the induction 
phases of EAE. (A) Encephalitogenic cells were prepared by immunizing WT 
mice and culturing their spleen cells in the presence of MOG and IL-12 for
3 d. 107 cells were injected i.p. into sublethally irradiated (500 R) cPLA2  /  
or cPLA2  /  mice. EAE clinical scores were assessed as described in Fig 2. Data 
are shown as a mean clinical score   SE of eight cPLA2  /  mice and seven 
cPLA2  /  mice. The incidence of EAE in the cPLA2  /  group was 100% 
and was 50% in the cPLA2  /  group. The statistical significance of the
difference between the curves was determined using ANOVA, P   0.001. 
Data are representative of three independent experiments. (B) Encephalito-
genic cells were prepared by immunizing cPLA2  /  or cPLA2  /  mice and 
culturing their spleen cells in the presence of MOG and IL-12 for 3 d. 107 
cells were injected i.p. into sublethally irradiated (500 R) WT mice. EAE 
clinical scores were assessed as described in Fig 2. Data are shown as a 
mean clinical score   SE of 10 mice per group. The incidence of EAE in 
mice that were injected with cPLA2  /  cells was 70%; it was 90% in mice 
that were injected with cPLA2  /  cells. The statistical significance of the 
difference between the curves was determined using ANOVA, P   0.0001. 
Data shown are representative of two independent experiments.JEM VOL. 202, September 19, 2005 845
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these mice to induce EAE in WT recipients. Cells that were
isolated from cPLA2  /  and cPLA2  /  mice were able to
induce EAE in the WT recipients. However, cells that orig-
inated from cPLA2  /  mice induced less severe EAE with
delayed onset (Fig. 5 B). These results suggest that, in addi-
tion to playing a role in the effector phase, cPLA2  plays a
role in the induction phase of the disease.
Development of Th1-type responses is impaired 
in cPLA2  /  mice
To assess why cells from the immunized cPLA2  /  mice
did not induce EAE that was as severe as that observed with
cells from cPLA2  /  controls, we tested antigen-specific
proliferation of these effector cells. In the presence of various
amounts of MOG, spleen cells that were isolated from
cPLA2  /  and cPLA2  /  control animals proliferated
similarly (Fig. 6 A). The proliferation of both types of cells
was reduced in the presence of IL-12, but cells from
cPLA2  /  and cPLA2  /  animals proliferated similarly
(Fig. 6 B). However, when we measured the amounts of
Figure 6. Proliferation and cytokine production by splenic cells from 
immunized cPLA2  /  and cPLA2  /  mice stimulated with MOG. The 
mice were immunized at two sites s.c. with MOG/CFA, and spleens were col-
lected 10 d later. T cell stimulation was set up in the presence of various con-
centrations of MOG and in the (A) absence or (B) presence of 30 ng/ml IL-12. 
Cells were cultured for 62–72 h and pulsed with [3H]thymidine during the last 
14–18 h of culture. Proliferation data are shown as a mean cpm   SD of six 
wells. Supernatants were collected after 48 h of culture and the amounts of 
(C) IFN-  and (D) TNF were determined in the pools of supernatants of six 
wells. Data shown are representative of two independent experiments.
Figure 7. Absence of IL-12 during the culture period impaired the 
ability of T cells from cPLA2  /  mice to induce EAE. Encephalitogenic 
cells were prepared by immunizing cPLA2  /  or cPLA2  /  mice and 
culturing their spleen cells in the presence of MOG without addition of 
exogenous IL-12. In two independent experiments, (A) 107 or (B) 4.5   107 
cells were injected i.p. into sublethally irradiated (500 R) WT mice. EAE 
clinical scores were assessed as described in Fig 2. (A) Data are shown as a 
mean clinical score   SE of 10 mice/group. The incidence of EAE in mice 
that were injected with cPLA2  /  cells was 50%; it was 10% in mice that 
were injected with cPLA2  /  cells. The statistical significance of the 
difference between the curves was determined using ANOVA, P   0.0001. 
(B) Data are shown as a mean clinical score   SE of 10 cPLA2  /  mice 
and 9 cPLA2  /  mice. The incidence of EAE in mice that were injected 
with cPLA2  /  cells was 100%; it was 50% in mice that were injected 
with cPLA2  /  cells. The statistical significance of the difference between 
the curves was determined using analysis of variance, P   0.0001.cPLA2 -DEFICIENT MICE ARE RESISTANT TO EAE | Marusic et al. 846
various cytokines in these MOG-stimulated cultures, a strik-
ing reduction in IFN-  levels was observed in cultures of
cPLA2  /  cells when compared with cPLA2  /  controls
(Fig. 6 C). These reduced IFN-  levels could be restored, in
part, by adding IL-12 to the cultures (Fig. 6 C). In addition,
levels of TNF, another Th1 cytokine, were reduced dramat-
ically in cPLA2  /  cultures in comparison with the con-
trols. TNF production was not restored upon addition of IL-
12 to the cultures (Fig. 6 D). As an indication that there was
no skewing toward Th2-type responses, there were no de-
tectable levels of IL-4 or -5 in cPLA2  /  or cPLA2  / 
cultures (unpublished data).
To test a potential role of exogenously added IL-12 dur-
ing the in vitro generation of encephalitogenic cells from
cPLA2  /  mice, we performed an adoptive transfer experi-
ment in which no IL-12 was added during the culture
period. When EAE was induced using cells that were cul-
tured in the absence of exogenously added IL-12, an even
greater difference in the ability of cells from cPLA2  /  and
cPLA2  /  mice to induce EAE was observed. When 107
encephalitogenic cells were used to induce EAE, the cells
that originated from cPLA2  /  mice induced mild clinical
EAE, whereas cells from cPLA2  /  mice induced almost
no clinical EAE (Fig. 7 A). When higher numbers of en-
cephalitogenic cells were used (4.5   107) to induce EAE,
cPLA2  /  cells induced severe disease, whereas cells from
cPLA2  /  mice induced mild disease with a delayed onset
(Fig. 7 B). These results indicate that when IL-12 is added to
the cultures of MOG-specific T cells, it contributes to the
generation of encephalitogenic cells and may mask endoge-
nous defect in their development.
We next tested if T cells that were isolated from
cPLA2  /  mice have an intrinsic defect in producing
Th1-type cytokines or if this defect was acquired during
the priming in vivo. We separated CD4  and non-CD4 
cells (designated APCs thereafter) from the draining LNs
of MOG-immunized cPLA2  /  and cPLA2  /  mice.
When CD4  cells and APC cells were from cPLA2  / 
mice, stimulation by MOG produced eight- and fivefold
lower levels of IFN-  and TNF, respectively, compared
with the levels that were produced in co-cultures of the
cells from cPLA2  /  mice (Fig. 8). Much of this difference
was maintained when CD4  cells from cPLA2  /  and
cPLA2  /  mice were stimulated with APCs from the
cPLA2  /  mice. However, the source of APCs did have an
effect on IFN-  levels when CD4  cells from cPLA2  / 
mice were stimulated with MOG and APCs from cPLA2  / 
mice. The levels of IFN-  produced were almost twice as
high as the levels that were produced in cultures in which
APCs were from cPLA2  /  mice. Changing the source of
APCs had no effect on the levels of TNF that were pro-
duced in these cultures. To test if the defect in Th1 cytokine
production was limited to MOG-specific T cells or was at-
tributed to of all T cells from cPLA2  /  mice, the cultures
were stimulated with anti-CD3 mAb’s. In these cultures, T
Figure 8. The defect in production of Th1-type cytokines in cells 
from cPLA2  /  is acquired during in vivo priming. CD4  cells and 
non-CD4  cells (APCs) were isolated from the draining LNs of cPLA2  /  
or cPLA2  /  mice that were immunized previously with MOG/CFA. CD4  
cells and APCs from the two types of mice were mixed and the ability of 
cells in these cultures to produce (A) IFN-  or (B) TNF was measured after 
stimulation with MOG (20  g/ml) or anti-CD3 (1  g/ml).
Figure 9. Administration of IL-12 renders cPLA2  /  mice susceptible 
to EAE. cPLA2  /  or cPLA2  /  mice were immunized with MOG/CFA 
and injected with pertussis toxin on day 0. Then cPLA2  /  mice received 
PBS or IL-12 (0.1 mg/dose) i.p. on days 1, 3, 5, 7, and 9. EAE clinical scores 
were assessed as described in Fig 1. Data are shown as a mean clinical 
score   SE of 10 cPLA2  /  mice that were treated with PBS, 8 cPLA2  /  
mice that were treated with IL-12, and 10 untreated cPLA2  /  mice. The 
incidence of EAE was 20% for PBS-treated cPLA2  /  mice, 75% for IL-12–
treated cPLA2  /  mice, and 100% for cPLA2  /  mice. The statistical 
significance of the difference between the curves for PBS-treated 
cPLA2  /  mice versus IL-12–treated cPLA2  /  mice was determined 
using ANOVA, P   0.0001. There was no statistically significant difference 
between the curves for IL-12–treated cPLA2  /  mice versus cPLA2  /  
mice as determined using analysis of variance, P   0.416.JEM VOL. 202, September 19, 2005 847
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cells from cPLA2  /  and cPLA2  /  mice produced simi-
lar levels of IFN- , regardless of the source of the APCs.
Amounts of TNF produced by cPLA2  /  CD4 cells were
lower ( 30%) than amounts of TNF that were produced by
CD4  cells from cPLA2  /  mice. This indicated that an
intrinsic defect in production of TNF may exist in cells from
cPLA2  /  mice. However, this defect is much less pro-
nounced than the fivefold defect in TNF that was observed
for MOG-specific T cells from cPLA2  /  mice.
Injection of IL-12 during disease induction period renders 
cPLA2
 /  mice susceptible to EAE
The data obtained in the above-described studies indicated
that Th1 differentiation is impaired in cPLA2  /  animals.
Therefore, we tested whether injection of recombinant
mouse IL-12, a potent inducer of Th1 differentiation, dur-
ing the immunization phase would render cPLA2  /  mice
susceptible to EAE. When cPLA2  /  mice were immu-
nized with MOG/CFA and injected with 0.1  g recombi-
nant murine IL-12 on the day of immunization and every
other day after that for a total of five injections, most of the
cPLA2  /  mice developed EAE (Fig. 9).
DISCUSSION
In the present study, we demonstrate that cPLA2  is essential
for the development of EAE. cPLA2  plays a role in the in-
duction of the encephalitogenic immune responses and in
the effector phase of EAE. cPLA2  plays an important role
in enhancing the production of Th1-type cytokines. The
defect in Th1-type cytokine production and the reduced en-
cephalitogenic potential of cPLA2  /  cells can be reversed,
in part, by providing exogenous IL-12. Similarly, in vivo ad-
ministration of IL-12 during the induction phase of the dis-
ease can render cPLA2  /  mice susceptible to EAE.
During the course of EAE development, we detected sig-
nificant increases in the levels of PGE2 and LTB4, which were
indicative of PLA2 activation during the peak and recovery of
the disease. This is consistent with the published observation
that the levels of cPLA2  are increased during EAE develop-
ment (22), and with the observation that these mediators are
increased in CSF of patients who have MS (17).
When immunized with MOG, cPLA2  /  mice were
almost completely resistant to EAE induction. Our finding is
consistent with the previously published report that treat-
ment of MOG-immunized mice with AACOCF3, which
inhibits cPLA2 , inhibits development of EAE in a dose-
dependent manner (22). The observed clinical resistance to
EAE development was confirmed by microscopic examina-
tion of the brains and spinal cords, which revealed a great re-
duction in the number of inflammatory foci in the CNS tis-
sues from the immunized cPLA2  /  mice, compared with
cPLA2  /  mice. However, several immunized cPLA2  / 
mice had reduced, but detectable, inflammation in CNS in
the absence of clinical signs of EAE. Such clinically silent in-
flammatory lesions have been described in MOG-induced
EAE in mice and rats (37, 38), and clinically silent MRI le-
sions are common in patients who have MS (39). It has been
suggested that the size and location of the lesions, as well as
their ability to recruit macrophage/microglia may be related
to the clinical silence of the lesions (37–39). The presence of
these inflammatory lesions in  50% of cPLA2  /  mice
demonstrates that MOG-specific T cells that are capable of
entering the CNS were generated in cPLA2  /  mice.
There are at least two possible explanations for the lack of
clinical signs in these mice. First, it is possible that in
cPLA2  /  mice, the number of encephalitogenic cells or
their function is not adequate for a full development of EAE.
In this case, the induction phase of EAE would be deficient
in cPLA2  /  mice. Second, it is possible that encephalito-
genic T cells, once in the CNS, are not able to mediate full
EAE development. In this latter case, resistance to EAE in-
duction in cPLA2  /  mice would be a result of a defective
effector phase of EAE. It is well-established that encephalito-
genic T cells represent only a small fraction of the cells in the
inflammatory lesions, whereas most of the cells are recruited
to the site in an antigen-independent manner (25, 40).
To determine whether cPLA2  plays a role in the induc-
tion or the effector phase of EAE, we used the adoptive
transfer model of the disease. Transfer of encephalitogenic
cells that were generated from immunized WT donors into
cPLA2  /  recipients resulted in EAE with the same time of
onset, but lesser severity, compared with transfer of the same
cells into cPLA2  /  recipients. This indicates that cPLA2 
plays a role in the effector phase of EAE, and is consistent
with the previous report that cPLA2  is expressed by endo-
thelial cells and macrophages as well as CD4  T cells in the
EAE lesions (22). Multiple downstream products of cPLA2 
enzymatic activity may play a role in enhancing and sustain-
ing inflammatory responses in CNS during the effector phase
of EAE. For example, LTB4 is a potent chemoattractant of
myeloid cells as well as CD4 and CD8 effector cells (41–44).
In addition, LTs enhance phagocytic capacity and the gen-
eration of other proinflammatory mediators by leukocytes
(45). In addition to generating AA, cPLA2  also generates
the lysophospholipid precursor of PAF—which may play an
important role during the effector phase of EAE—by acting
as a strong chemoattractant and by increasing the permeabil-
ity of blood–brain barrier, and thereby, facilitating entry of
proinflammatory cells into CNS (24, 46). Recent work by
Kihara et al. (47) showed that PAF receptor–deficient mice
have reduced incidence and severity of EAE.
Because active immunization of cPLA2  /  mice re-
sulted in almost no clinical EAE, whereas the adoptive trans-
fer of encephalitogenic cells into cPLA2  /  mice resulted
in mild but significant EAE, we considered the possibility
that cPLA2  also plays a role in the induction of encephali-
togenic immune responses. We compared EAE develop-
ment in WT recipient mice that were injected with enceph-
alitogenic cells that were generated from MOG-immunized
cPLA2  /  or cPLA2  /  mice. EAE that was induced by
cPLA2  /  cells had a delayed onset and lower severity
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showed that cPLA2  also plays a role in the induction of en-
cephalitogenic immune response.
The reduced encephalitogenic potential of the cPLA2  / 
cells coincided with reduced production of IFN-  and
TNF by these cells in vitro without an increase in Th2-type
cytokines. At the same time, there was no reduction in
MOG-stimulated proliferation of T cells from immunized
cPLA2  /  mice, which indicated that priming and expan-
sion of MOG-specific T cells was not affected by the defect
in cPLA2 . The defective production of Th1-type cytokines
could be restored, in part, by the addition of IL-12 to the
cultures. Addition of IL-12 also enhanced the encephalito-
genic potential of cells that were isolated from cPLA2  / 
mice. When IL-12 was omitted from the cultures, cells that
were isolated from cPLA2  /  mice had an even lower abil-
ity to induce EAE. Conversely, in vivo administration of IL-
12 during the immunization period restored the ability of
these mice to develop EAE, which further suggests that at
least part of the defect in developing EAE in these mice may
be related to the defective differentiation toward Th1-type
responses. Our preliminary experiments have shown that
adoptive transfer of up to 25 million CD4  T cells from
cPLA2  /  mice into cPLA2  /  mice does not render
cPLA2  /  mice susceptible to EAE. Further experiments
are required to determine which cells need to produce
cPLA2  for Th1-type responses to develop. Our results in-
dicate that CD4  cells from cPLA2  /  mice do not have an
intrinsic defect in the production of Th1-type cytokines. In-
stead, the defect was acquired during T cell priming in vivo.
The mechanism by which cPLA2 -mediated AA release
may enhance development of Th1 responses is not known.
cPLA2 -mediated AA release was shown to be critical in
MCP-1–, MCP-3–, regulated on activation, normal T cell
expressed and secreted–, and monocyte inflammatory pro-
tein-1 –mediated activation and migration of human
monocytes (48); therefore, it is possible that macrophage re-
cruitment and/or activation is impaired in cPLA2  /  mice.
Macrophages are believed to be a major effector cell in the
EAE inflammatory response, and the severity of EAE corre-
lates with the number of macrophages detected in the CSF
of mice that have EAE (25, 49, 50). Mice that are deficient
in MCP-1 or its receptor, CCR2, have reduced numbers of
macrophage infiltrates and are resistant to EAE development
when injected with WT encephalitogenic T cells (51, 52). It
is noteworthy that serum levels of IFN-  were reduced sig-
nificantly in MCP-1 /  mice at the time of peak disease,
which indicated an impaired Th1 response that was analo-
gous to that seen in the cPLA2  /  mice (52). Unlike cells
that were isolated from cPLA2  /  mice, MCP-1 /  T cells
were fully encephalitogenic when transferred to WT mice.
However, as the investigators noted, IL-12 that was present
during generation of these encephalitogenic cells may have
masked the defect in Th1 differentiation (52). Thus, it is
possible that in the absence of cPLA2 , MCP-1/CCR2-
mediated macrophage trafficking and/or activation is im-
paired, which results in reduced tissue injury and insufficient
development or maintenance of Th1 effector cell function.
Products of cPLA2  also may play a role in Th1/Th2
differentiation. Although it is possible that LTs also regulate
skewing of Th1/Th2 cells, we do not believe that LTs are
critical for initial skewing toward Th1 responses in the EAE
model, because 5-LO–deficient mice develop EAE with a
similar time of onset and increased severity when compared
with control mice (53). Conflicting data exist on the possible
role of PG in IL-12 induction. For example, it was demon-
strated that exposure of bone marrow–derived immature
DCs to PGE2 suppresses IL-12 production by these cells by
way of increased IL-10 production (54) which would lead to
decreased Th1 differentiation. In contrast, PGE2 was dem-
onstrated to enhance IL-12 production when immature DCs
were stimulated with TNF (55). It is possible that multiple
lipid mediators can influence Th1/Th2 cell differentiation
by affecting multiple cell types. The effects of these media-
tors may be influenced further by the presence of other in-
flammatory mediators at the site of inflammation, and it is
possible that the same lipid mediator may have opposite ef-
fects under different in vivo conditions. It also is possible that
cPLA2  /  mice have deficient Th1 responses because of
reduced IL-23 production. PGE2 and pharmacologic ago-
nists of the prostaglandin E2 receptor (EP)2 and EP2/EP4 re-
ceptors recently were shown to induce IL-23 production
from unstimulated immature DCs (56). cPLA2 -deficient
mice recently were shown to be resistant to induction of
collagen-induced rheumatoid arthritis, another autoimmune
disease that is believed to be mediated primarily by Th1 re-
sponses, in which macrophages are believed to be major cells
that mediate the autoimmune pathology (57).
In conclusion, we demonstrated that cPLA2  is necessary
for EAE development and that this enzyme plays a role during
the induction and the effector phases of EAE. In the absence
of cPLA2 , induction of Th1-type responses is impaired; we
suggest that cPLA2  may represent a novel therapeutic target
for treatment of MS and other Th1-mediated diseases.
MATERIALS AND METHODS
Mice. cPLA2  /  mice on C57BL/6 background were generated by
backcrossing cPLA2  /  mice of mixed B6/129 background (21) to B6
background for 12 generations and then intercrossing cPLA2  /  mice
to obtain cPLA2 WT, cPLA2  / , and cPLA2  /  mice, or crossing
cPLA2  /  and cPLA2  /  mice to obtain cPLA2  /  and cPLA2  /  lit-
termates. All cPLA2  mice were bred at Taconic Farms and were used at
6–10 wk of age. In all experiments, age- and sex-matched littermates were
used to compare cPLA2  /  with cPLA2  /  and/or cPLA2 WT mice.
For some experiments, WT female C57BL/6 mice were purchased from
Jackson ImmunoResearch Laboratories or Taconic Farms and used at 6–10
wk of age. These mice were used only when no direct comparison was
done to cPLA2  /  mice. Wyeth Institutional Animal Care and Use Com-
mittee was the overseeing body that approved the animal studies.
EAE induction. For EAE induction using immunization with MOG, all
mice were injected s.c. at two sites with a total of 200  g of MOG peptide
35–55 in CFA containing 6 mg/ml killed Mycobacterium tuberculosis. On the
same day, the mice received 500 ng pertussis toxin (List Laboratories) i.p. ForJEM VOL. 202, September 19, 2005 849
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EAE induction in the adoptive transfer model, recipient mice were irradiated
sublethally (500 R) and within 16 h were injected i.p. with encephalitogenic
cells, prepared as described below. Paralysis (clinical evidence of EAE) was
assessed daily, starting on day 5 after immunization or adoptive transfer,
when all the mice were still clinically normal. Clinically, animals were scored
as follows: 1, limp tail; 2, partial hind leg paralysis; 3, complete hind leg pa-
ralysis or partial hind and front leg paralysis; 4, complete hind and partial
front leg paralysis; 5, complete hind and partial or complete front paralysis
with severely reduced responsiveness to external stimuli. Mice were killed
immediately if they scored 5, or if they scored 4 on two consecutive days.
Preparation of cells for EAE induction in adoptive transfer model.
To prepare MOG-specific cells that were able to induce EAE in the adop-
tive transfer model, mice were immunized with MOG/CFA in the same
fashion as when inducing EAE, but no pertussis toxin was administered.
Spleens were collected 10 d later, single-cell suspension was prepared and
red blood cells were lysed. Stimulation with MOG was performed in T150
flasks, using 6   106 cells/ml and 20  g MOG35–55/ml in T cell medium
(RPMI media enriched with 10% FBS, 2 mM L-glutamine, 5   10 5 M
2-ME, nonessential amino acids, sodium pyruvate, and penicillin/strepto-
mycin). Recombinant mouse IL-12 was added to some cultures at 30 ng/
ml. 3 d after initiation of the cultures, cells were harvested, washed in PBS,
and injected into recipient mice as described above for EAE induction.
Histology. Mice were killed using CO2 asphyxia and immediately per-
fused with 10–20 ml of cold PBS. The head and spine were dissected in one
piece, and a hole was made in the skull to allow formalin to enter the sub-
arachnoid space. The tissue was immersed into 10% buffered formalin and
fixed for at least 72 h before processing. After fixation, brains were removed
from the skull before sectioning. Spinal columns with spinal cords were de-
calcified before sectioning in situ. Four transverse sections of the brain
(frontal cortex to medulla), and multiple (n   9 to 13 sections/animal)
transverse sections of the cervical, thoracic, and lumber spinal cord were
prepared routinely and stained with hematoxylin and eosin. Spinal cord sec-
tions also were stained with Luxol fast blue. The number of inflammatory
foci that contained at least 20 cells were counted in each hematoxylin and
eosin–stained section in a blinded fashion by the same pathologist (MWL)
(58, 59). When foci were coalescing, estimates were made of the number of
foci. The presence of vacuolation and pallor in the white matter also were
noted. Demyelination was assessed on Luxol fast blue sections.
Determination of PGE2 and LTB4 mediators in mouse spinal
cords. At different time points during EAE development, mice were killed
and extensively perfused with cold PBS (at least 20 ml/mouse). The spinal
cords were collected from the animals (two to six spinal cords were pooled
together, at least three pools were collected at each time point) and imme-
diately homogenized in methanol. The mediators in the tissues were ex-
tracted in 5 ml methanol for 3–5 d at  80 C. To remove the tissue resi-
dues, the extracts were centrifuged at 1,800 g for 20 min at 4 C. Then the
sample solutions were dried to remove methanol. The dried samples were
suspended in an assay buffer that was supplied with each ELISA kit (Assay
Designs). To determine the levels of PGE2 and LTB4 within the sensitive,
(i.e., linear) ranges of the standard curves, the samples were diluted further
1–20 fold and assayed at multiple dilutions.
T cell proliferation and cytokine production analysis. To assess
draining LN T cell proliferation and cytokine production against MOG, we
immunized mice at the base of the tail with MOG/CFA (using the same
amount of MOG and CFA as in EAE induction protocol) and collected in-
guinal LNs 10 d later. Single-cell suspensions were prepared, and in some
experiments, CD4  and non-CD4  (APC) cells were isolated using Dynal
beads (Invitrogen), according to the manufacturer’s instructions. When
CD4  and non-CD4  cells were isolated, they were mixed at 1:1 ratio. 8  
105 cells/well were cultured in 96-well plates in T cell medium and various
amounts of MOG peptide or anti-CD3 antibodies. 48–54 h after the initia-
tion, the culture supernatants were collected for cytokine analysis and the
cultures were pulsed with 0.5  Ci of [3H]thymidine/well and harvested
14–18 h later.
To assess proliferation and cytokine production of splenic T cells against
MOG, mice were immunized with MOG/CFA in the same fashion as when
inducing EAE, but no pertussis toxin was administered. Spleens were col-
lected 10 d later, single-cell suspensions were prepared, and red blood cells
were lysed. Stimulation with MOG was performed as described above for
LN cells. Culture supernatants were collected 48 h later for cytokine analysis
and cultures were pulsed to determine [3H]thymidine incorporation. Con-
centrations of IL-4, IL-5, IFN- , and TNF in the supernatants were quanti-
fied using a cytometric bead array kit obtained from BD Biosciences.
Statistical analysis. For statistical analysis, a Poisson distribution was used
to model the inflammatory foci parameter. A square root transformation
was applied to stabilize the variance, and then the transformed data were an-
alyzed with a one-way analysis of variance. Severity scores were analyzed
using the mean score Mantel-Haenszel statistic. Clinical scores were com-
pared using analysis of variance. Statistical significance of differences in cy-
tokine production and lipid mediator presence in spinal cords was deter-
mined using Student’s t test.
Online supplemental material. Table S1 shows that effector cells from
spleen or lymph node induce EAE in sublethally irradiated, but not in non-
irradiated, recipient mice. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20050665/DC1.
Statistics on the microscopic changes were done by Dr. Y. Huang.
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